The power of preclinical imaging in radiotheranostic research

Tracking and monitoring target specificity and safety profiles is essential to the evaluation of new immuno- and radiotherapeutic candidates in theranostics research during the preclinical phase. Nuclear imaging modalities, including micro-PET and micro-SPECT, are crucial tools for monitoring diagnostic and therapeutic potential in a physiologically relevant way and allows for longitudinal studies, enabling in-depth safety and evaluation of pharmacokinetic and biodistribution profiles, permitting higher success rates downstream. Nuclear imaging with the CUBES provides an efficient, high-throughput solution to aid in the rapidly growing field of theranostics.